XHKG1801
Market cap7.39bUSD
Dec 23, Last price
35.05HKD
1D
-0.43%
1Q
-15.34%
IPO
106.66%
Name
Innovent Biologics Inc
Chart & Performance
Profile
Innovent Biologics, Inc. operates as a biopharmaceutical company in China. The company operates a platform for the discovery, development, and manufacture of antibody drug candidates in the fields of oncology, ophthalmology, immunology, and metabolic diseases. Its principal drug candidate is Tyvyt (sintilimab), an anti-PD-1 monoclonal antibody for the treatment of cancer, Hodgkin's lymphoma, and esophageal carcinoma. The company also offers Byvasda for the treatment of several malignant tumors; Halpryza for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and Wegener's granulomatosis; Pemazyre for the treatment of adults with locally advanced or metastatic cholangiocarcinoma; Olverembatinib for the treatment of adult patients with tyrosine kinase inhibitor; and Cyramza to treat four different types of cancers. In addition, it engages in the development of IBI-301, a rituximab biosimilar for non-Hodgkin's lymphoma; IBI-302, a bispecific antibody fusion protein for ocular fundus disease; IBI-306, a human monoclonal antibody to treat hypercholesterolemia; IBI-310, a recombinant human anti CTLA-4 monoclonal antibody for liver cancer and renal cell carcinoma. Further the company develops IBI-188, an anti-CD47 monoclonal antibody for advanced hematological and solid tumors; IBI-326, a fully human BCMA-CAR T-cell therapy for the treatment of adults with relapsed or refractory multiple myeloma; IBI-376 for the treatment of recurrent or refractory follicular lymphoma; and IBI-112 for the treatment of psoriasis. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. The company has strategic collaborations with NeoCura Bio-Medical Technology Co. Ltd.; Roche Group; Ascentage Pharma Group International; Eli Lilly and Company; Roche Group; and Bolt Biotherapeutics, Inc. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
Income | ||||||||
Revenues | 6,206,070 36.21% | 4,556,380 6.71% | 4,269,729 11.08% | |||||
Cost of revenue | 7,885,371 | 7,228,463 | 6,663,300 | |||||
Unusual Expense (Income) | ||||||||
NOPBT | (1,679,301) | (2,672,083) | (2,393,571) | |||||
NOPBT Margin | ||||||||
Operating Taxes | (116,498) | 8,801 | 87,038 | |||||
Tax Rate | ||||||||
NOPAT | (1,562,803) | (2,680,884) | (2,480,609) | |||||
Net income | (1,027,913) -52.83% | (2,179,270) -30.55% | (3,138,053) 214.30% | |||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | 2,255,116 | 2,131,059 | 3,950,520 | |||||
BB yield | -3.38% | -4.27% | -5.62% | |||||
Debt | ||||||||
Debt current | 1,220,330 | 914,392 | 387,273 | |||||
Long-term debt | 2,498,796 | 2,439,191 | 2,218,318 | |||||
Deferred revenue | 883,277 | 753,274 | ||||||
Other long-term liabilities | 1,222,764 | 162,305 | 342 | |||||
Net debt | (8,044,592) | (5,624,226) | 828,928 | |||||
Cash flow | ||||||||
Cash from operating activities | 147,810 | (1,918,804) | (2,024,843) | |||||
CAPEX | (1,119,385) | (1,381,730) | (1,847,516) | |||||
Cash from investing activities | (998,662) | (1,435,185) | (2,698,148) | |||||
Cash from financing activities | 2,587,257 | 2,892,082 | 5,003,361 | |||||
FCF | (2,158,468) | (2,854,866) | (3,695,711) | |||||
Balance | ||||||||
Cash | 10,969,629 | 8,264,594 | 7,940,893 | |||||
Long term investments | 794,089 | 713,215 | (6,164,230) | |||||
Excess cash | 11,453,414 | 8,749,990 | 1,563,177 | |||||
Stockholders' equity | (15,767,456) | (15,917,404) | (12,163,261) | |||||
Invested Capital | 33,138,330 | 30,860,428 | 25,651,424 | |||||
ROIC | ||||||||
ROCE | ||||||||
EV | ||||||||
Common stock shares outstanding | 1,559,637 | 1,490,123 | 1,455,606 | |||||
Price | 42.75 27.61% | 33.50 -30.57% | 48.25 -39.69% | |||||
Market cap | 66,674,482 33.57% | 49,919,127 -28.92% | 70,232,977 -35.31% | |||||
EV | 58,629,890 | 44,294,901 | 71,061,905 | |||||
EBITDA | (1,294,198) | (2,352,661) | (2,188,824) | |||||
EV/EBITDA | ||||||||
Interest | 98,624 | 101,698 | 62,464 | |||||
Interest/NOPBT |